Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

NCT01237119 on ClinicalTrials.gov · last registry update 2016-03-23

A small phase 2 — 52 participants, against a typical 110. The sponsor logged completion for July 2014. Primary outcome, as filed: Liver Histological improvement. liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Birmingham
Sponsor type: Other
Enrollment: 52
Started: 2010-08
Primary completion: 2014-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Liver Histological improvement

Conditions studied

Nonalcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.